Replies to post #212581 on Biotech Values

[poorgradstudent]

RETA:

I think this type of situation is always a possibility.

The drug's impact on eGFR was not in doubt, and was published in the NEJM paper. The issue is how you finesse a drug that increases mortality in the long term versus this short term trial outcome.

This is a prime example of a "catalyst" field of view versus a long term fundamental view.

[DewDiligence]

RETA -8% on phase-1b data for Omaveloxolone/Opdivo in melanoma:

https://globenewswire.com/news-release/2017/12/11/1250708/0/en/Reata-Pharmaceuticals-Inc-Presents-Interim-Phase-1b-Data-for-Omaveloxolone-in-the-Treatment-of-Unresectable-or-Metastatic-Melanoma.html